Selective bcl-2 inhibitors in combination with an anti-pd-1 or an anti-pd-l1 antibody for the treatment of cancers
OwnerTamar Uziel, Joel D. Leverson +5inventors
InventorsTamar Uziel, Joel D. Leverson, William N. Pappano, Dipica B. Maganbhai Haribhai, Rebecca Mathew, Fred Kohlhapp, Cherie K. Donawho
Life of this patent
Estimating the term…
Abstract
This invention pertains to a method for the treatment of cancer in a subject comprising administering to the subject an effective amount of a selective BCL-2 inhibitor or a prodrug or pharmaceutically acceptable salt thereof in combination with an effective amount of an anti-PD-1 antibody or an anti-PD-L1 antibody.
Claims32
A method for the treatment of a hematologic cancer in a subject who is in need thereof, comprising administering to the subject an effective amount of either an anti-PD-1 (programmed cell death protein-1) antibody or an anti-PD-L1 (programmed death ligand-1) antibody in combination with an effective amount of a selective BCL-2 inhibitor or a prodrug or pharmaceutically acceptable salt thereof.
Methods for the treatment of solid tumor cancer in a subject who is in need thereof, comprising administering to the subject an effective amount of either an anti-PD-1 (programmed cell death protein-1) antibody or an anti-PD-L1 (programmed death ligand-1) antibody in combination with an effective amount of a selective BCL-2 inhibitor or pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.